Solutia Reports Third Quarter 20...(related expense less than co...)

Date:10/26/2009

related expense less than contributions (24) (39) (18) Other postretirement benefit obligation related expense less than contributions (8) --- (6) Deferred income taxes 3 (22) 5 Amortization of deferred debt issuance costs 15 10 -- Loss (gain) on sale of assets 5 (8) -- Other charges (gains) including restructuring expenses 19 67 (2) Changes in assets and liabilities: Income taxes payable 4 14 5 Trade receivables (42) 14 (24) Inventories 66 (19) (34) Accounts payable (18) 21 31 Environmental remediation liabilities (14) (7) (1) Restricted cash for environmental remediation and other legacy payments 24 12 -- Other assets and liabilities (34) 19 (2) --- --- --- Cash Provided by (Used in) Continuing Operations before Reorganization Activities 123 125 (16) Reorganization Activities: Establishment of VEBA retiree trust -- -- (175) Establishment of restricted cash for environmental remediation and other legacy payments -- -- (46) Payment for allowed secured and administrative claims -- -- (79) Professional service fees --
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009